Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

NCT05123482 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05123482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05123482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 18, 2021
Completion date
September 29, 2027
Enrollment
460 (estimated)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma, breast cancer, endometrial cancer, ovarian cancer, squamous non-small cell lung cancer